In a phase II trial conducted by Overman et al., which was the largest immunotherapy trial for CRC, a partial response to nivolumab (an anti-PD-1 antibody) administered either alone or in combination with ipilimumab was observed in 31% of patients with MSI and in 10% of patients with MSS [13]. This evidence concerns the gene RPL17 and colorectal carcinoma.